GLP-1 Purchase Prices in 2026: Forbes Maps Branded, Compounded and Medicare Costs
GLP-1 purchase prices in the United States now span a wide range, from roughly $50 per month for eligible Medicare Part D beneficiaries to self-pay figures starting at $149 for Wegovy and $100 to $300 per month for compounded versions, according to a Forbes Health explainer on semaglutide, tirzepatide and compounded GLP-1 costs. The report, published October 30, 2026, catalogues list prices, insurance copays, manufacturer savings programs and a new CMS program running from July 1, 2026 through December 31, 2027. For peptide therapy clinics, telehealth platforms and research-peptide suppliers, the price map matters because it sets the reference point against which every alternative supply channel is now judged.
Why it matters to the peptide sector: GLP-1 receptor agonists are peptides, and the price at which patients can obtain semaglutide or tirzepatide shapes demand for compounded formulations, clinic-supervised protocols and research-grade material. When branded self-pay prices fall, the commercial room for cheaper alternatives narrows; when insurance coverage remains inconsistent for obesity, patients keep searching for other routes. This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com.
What Forbes Health actually reported on GLP-1 prices
Forbes Health divides the category into two pharmacological classes. GLP-1 receptor agonists include semaglutide products: Wegovy is FDA-approved for chronic weight management and Ozempic is FDA-approved for management of type 2 diabetes. Dual GIP and GLP-1 receptor agonists include tirzepatide: Zepbound is FDA-approved for weight loss and Mounjaro is FDA-approved for treatment of type 2 diabetes. The article also notes that some GLP-1 medications FDA-approved to treat type 2 diabetes are prescribed off-label to support weight loss, a practice that places prescribing decisions with licensed clinicians rather than with product marketing.
On the mechanism, the report states that GLP-1 receptor agonists mimic the naturally occurring GLP-1 hormone, often causing a reduction in body weight, blood sugar and cardiovascular risk. It adds that some studies suggest dual GIP and GLP-1 receptor agonists may lead to greater weight loss and blood sugar improvements compared to certain GLP-1 receptor agonists, a comparative statement the source presents without effect sizes, trial names or sample sizes. Readers should treat that comparison as suggestive rather than settled.
Critically, the article says list prices are set by a manufacturer before any discounts or rebates are applied, and it references a table of list prices for common FDA-approved GLP-1s. The figures in that table are not reproduced in the text, so no specific list price can be attributed from this source.
The key numbers: self-pay, insurance and compounded costs
The concrete figures in the Forbes Health report cluster around self-pay and insurance scenarios. Self-pay prices for Wegovy start at $149, and Foundayo costs $149 to $349 for those who qualify for Eli Lilly’s savings program. Under NovoCare, new and existing users with commercial insurance coverage may pay as low as $25 for a one-month supply of Wegovy; new self-pay or uninsured users can pay $199 per month for the first two months under a limited-time introductory offer; and existing self-pay or uninsured users may pay $349 for a one-month supply.
With commercial insurance, patients can typically expect costs anywhere from $25 to $149 per month, according to Dr. Peter Balazs of Hormone and Weight Loss Doctors of NJ. Bracha Banayan, an ANCC-certified family nurse practitioner, notes that GLP-1 medications are often covered by insurance when a patient has diabetes, while coverage for obesity is not always consistent or guaranteed.
| Cost channel | Reported price | Conditions noted by source |
|---|---|---|
| Wegovy self-pay | From $149 | Self-pay pricing cited by Forbes Health |
| Foundayo self-pay | $149–$349 | Requires qualification for Eli Lilly savings program |
| NovoCare, Wegovy, commercial insurance | As low as $25/month | New and existing users with commercial coverage |
| NovoCare, Wegovy, new self-pay or uninsured | $199/month for first two months | Limited-time introductory offer |
| NovoCare, Wegovy, existing self-pay or uninsured | $349/month | One-month supply |
| Commercial insurance (typical) | $25–$149/month | Expert estimate from Dr. Peter Balazs |
| Compounded GLP-1s | $100–$300/month | Varies by dose and platform; usually not insured |
| Online platform membership | $40–$100/month average | Typically charged in addition to medication |
| CMS Medicare Part D program | $50/month | Some GLP-1 weight-loss medications; July 1, 2026–Dec 31, 2027 |
Compounded GLP-1s: cheaper, but not FDA-reviewed
Compounded GLP-1 medications are generally less expensive than branded versions, with approximate monthly costs between $100 and $300 depending on dose and platform, according to Dr. Balazs. Banayan attributes the gap to the fact that compounded products are not sold under major pharmaceutical brand pricing structures. Forbes Health also notes that compounded formulations can serve as an alternative when FDA-approved GLP-1s are not commercially available or when an individual’s medical needs cannot be met, for example an allergy to an ingredient.
The same report carries a clear regulatory caveat: compounded drugs are not reviewed by the FDA for safety, purity or efficacy. Dosing errors and contamination may pose health risks, and potential side effects cited include fungal infections, inflammation of the gallbladder and hospitalization. Compounded GLP-1 medications are also usually not covered by insurance. For clinics weighing a compounded or research-grade supply route against branded product, that distinction between an FDA-approved drug, a compounded drug and a research-use-only chemical is the first documentation question to settle.
PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates.
Why the price map matters for peptide therapy clinics and telehealth
For clinic operators, the Forbes Health figures function as a benchmark rather than a menu. A telehealth platform that charges a $40 to $100 monthly membership on top of medication, as Dr. Balazs describes, is competing against a $25 NovoCare copay for insured Wegovy users and a $50 Medicare program price. That compression at the low end may push differentiation toward clinical oversight, documentation and follow-up rather than headline drug price.
Supply-side decisions follow the same logic. Clinics sourcing peptide active pharmaceutical ingredients or finished vials need batch-level documentation, and the industry distinction between a peptide API and a finished peptide drug is not cosmetic: an API certificate of analysis does not establish finished-product quality or regulatory approval. Buyers evaluating a supplier should confirm identity, purity method, impurity profile, storage requirements and traceability before treating any material as comparable to an approved product. Platforms such as peptidescm aggregate supplier and supply-chain information that clinics can use to structure those requests.
Safety counselling is part of the same commercial equation. The most common side effects of GLP-1 medications are gastrointestinal, including nausea, vomiting, diarrhea, constipation and decreased appetite, and clinicians cited by Forbes Health note that some patients also report fatigue or mild abdominal discomfort that often improves as the body adjusts. GLP-1 medications require a prescription from a licensed medical provider, and any clinic protocol should keep prescribing and supervision with qualified professionals.
Medicare, savings programs and the direction of coverage
The most significant structural item in the report is the CMS program: as of July 2026, the Centers for Medicare and Medicaid Services has rolled out a program offering access to some GLP-1 weight-loss medications at $50 per month for people with Medicare Part D coverage, running from July 1, 2026 through December 31, 2027. The source does not specify which medications are included, so eligibility and formulary details must be checked individually.
Manufacturer direct cash-pay channels, such as LillyDirect and NovoCare, let patients bypass insurance, according to Dr. Balazs, and assistance programs may provide medication free to patients who meet certain income requirements. Dr. Balazs also notes that GLP-1 coverage is still evolving, with recent and ongoing federal discussions, including Trump-era proposals, examining expanded coverage and lower prices. No enacted policy beyond the CMS program is documented in the source, so that trajectory should be read as uncertain.
What comes next for GLP-1 pricing and peptide supply
Three things are worth watching. First, whether the CMS program’s formulary list and uptake data become public before its December 31, 2027 sunset. Second, whether manufacturer self-pay prices continue to fall toward compounded levels, which would reshape the economics of alternative supply. Third, whether insurance coverage for obesity stabilizes, since inconsistent coverage is the gap that compounded and clinic-supervised routes currently fill.
For research-peptide businesses, the compliance line remains fixed: research-use labeling does not establish sterility, safety or suitability for human administration, and a certificate of analysis does not by itself guarantee that a sample is safe for humans. Forbes Health notes that prices are accurate at the time of publication but subject to change, and that costs vary by insurance coverage, pharmacy and available discounts. Any purchasing decision should be re-verified against current labeling and program terms.
FAQ
How much do GLP-1 medications cost per month in the U.S.?
Reported ranges vary by channel: $25 to $149 per month with commercial insurance, from $149 for Wegovy self-pay, $100 to $300 for compounded versions, and $50 per month for some GLP-1 weight-loss medications under the CMS Medicare Part D program running July 1, 2026 through December 31, 2027.
Are compounded GLP-1s cheaper than Wegovy or Zepbound?
Generally yes, at roughly $100 to $300 per month depending on dose and platform, according to Dr. Peter Balazs. Compounded drugs are not reviewed by the FDA for safety, purity or efficacy and are usually not covered by insurance.
Do I need a prescription for GLP-1 medications?
Yes. GLP-1 medications require a prescription from a licensed medical provider, and decisions about approved versus off-label use should be made with a clinician.
What is the difference between semaglutide and tirzepatide?
Semaglutide acts on the GLP-1 receptor, while tirzepatide activates both GIP and GLP-1 receptors. Their approved products, indications, dosing and labeling differ, and medical decisions should follow the relevant product labeling.